Quarterly Activities Report /Appendix 4C Cash Flow Statement

• Cash reserves of $5.47 million at March 2026, up from $1.83 million in December 2025
• Signed Cadila Pharmaceuticals licence and supply agreement for two generic medicines
• Entered exclusive agreement with Zydus Lifesciences for 10 pharmaceutical products in ANZ

Algorae Pharmaceuticals Ltd (ASX: 1AI) reported its activities and cash flow for the quarter ended 31 March 2026. The company's cash reserves increased to approximately $5.47 million at the end of the quarter, up from $1.83 million at 31 December 2025, reflecting net financing inflows of $3.98 million from option exercises and equity issuances. Algorae continued to advance its commercial pharmaceutical strategy, executing a definitive Licence & Supply Agreement with Cadila Pharmaceuticals for two generic medicines targeting cardiovascular and metabolic disorders. The company also entered an exclusive commercial and licensing agreement with Zydus Lifesciences Ltd for a portfolio of 10 injectable, oral and specialty pharmaceutical products across Australia and New Zealand. On the R&D front, Algorae commenced a second independent preclinical validation program with the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre, screening 24 high-priority drug combination candidates. The company also strengthened its commercial leadership team with the appointments of David Gulland as Chief Operating Officer and Waleed Elsayed as Head of Sales.